prof. dr. Fritz Offner
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - Fritz.Offner@UGent.be
- ORCID iD
-
0000-0003-4690-3603
Show
Sort by
-
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
-
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential
-
Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open label, phase 2 trial
-
- Conference Paper
- open access
Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial
-
Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation
-
- Journal Article
- open access
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
-
- Journal Article
- A1
- open access
Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies
-
- Journal Article
- A1
- open access
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
-
Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age : results with 5 years of follow-up for the RESONATE-2 study
-
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil : final analysis of the Complement 1 phase 3 trial